Next Article in Journal / Special Issue
Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein
Previous Article in Journal
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Vaccines 2019, 7(1), 20;

Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine

Department of Molecular and Clinical Medicine, Jacqui Woods Centre, Ninewells Hospital, Medical School, University of Dundee, Ninewells Drive, Dundee DD1 9SY, UK
Authors to whom correspondence should be addressed.
Received: 11 January 2019 / Revised: 4 February 2019 / Accepted: 7 February 2019 / Published: 12 February 2019
Full-Text   |   PDF [766 KB, uploaded 18 February 2019]   |  


Background: The development of therapeutic vaccines requires thorough knowledge of potential hazards associated with long-term inactivation of self-proteins. Among potential targets, interleukin 13 (IL-13) merits consideration, as monoclonal antibodies disrupting IL-13 signaling are proving to be exceedingly effective in common conditions such as atopic dermatitis. Objective: Given the mass publication of scientific data, an appraisal of safety aspects is challenging. Methods: We here provide a three-fold approach to survey clinically relevant information on off-target effects, both adverse and beneficial, that may potentially be encountered in patients undergoing long-term IL-13 inactivation. First, we review non-clinical data in vivo and in vitro. Second, we summarize safety data accumulating from patients dosed with anti-IL-13 drugs. Third, we exploit human mutation data as well as emerging large-scale genetic datasets (global exome data from 60,000 patients) to obtain information on any association of IL-13-inactivating genetic variants with disease states. In addition, we: (1) dissect the precise efficacy signals obtained with various drugs targeting IL-13 and/or IL-4, and (2) summarize unintended, but potentially beneficial effects of prolonged IL-13 inactivation on several functional systems. Results: Prolonged repression of IL-13 in several thousand patients so far has not uncovered any non-redundant functions of IL-13 in immune defense. Furthermore, missense mutations in the key genes IL-13, IL-13Rα1, IL-13Rα2, IL-4, IL-4Rα are common, while no case reports have been published on any immune deficiency or increased risk of neoplastic disease associated with such mutations, suggesting that these genes do not harbor non-redundant roles in adult outbred humans. In terms of efficacy, data from clinically used drugs strongly suggest that targeting IL-13 only, as opposed to IL-13 and IL-4, may be effective in eczema while being more selective. Importantly, several lines of evidence suggest that inhibition of IL-13 may in fact harbor potentially beneficial effects on non-targeted systems, including glucose metabolism, hepatic fibrosis, and atherosclerosis, suggesting that respective outcomes should be systematically captured in patients dosed with IL-13 interfering drugs. Collectively, available evidence suggests that IL-13 may fulfill safety requirements required for the target of a therapeutic vaccine. View Full-Text
Keywords: vaccine; VLP; IL-13; drug safety; IL-4; atopic dermatitis; asthma vaccine; VLP; IL-13; drug safety; IL-4; atopic dermatitis; asthma

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Foerster, J.; Molęda, A. Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine. Vaccines 2019, 7, 20.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top